Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

You may be eligible if

• Histologically confirmed adenocarcinoma of the pancreas
• * Locally advanced disease
• * Unresectable disease
• All malignant disease must be encompassable within a single irradiation field
• Radiographically assessable disease
• Patients with biliary or gastroduodenal obstruction are eligible provided drainage or surgical bypass was performed prior to initiation of study treatment
• No evidence of gastric outlet obstruction
• No evidence of duodenal invasion on CT scan
• No evidence of metastatic disease in the major viscera
• No peritoneal seeding or ascites
• Performance status - Zubrod 0-1
• Granulocyte count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• No evidence of bleeding diathesis
• ALT \< 3 times upper limit of normal
• Bilirubin \< 2.0 mg/dL
• INR ≤ 1.5
• No evidence of coagulopathy
• Creatinine clearance \> 50 mL/min
• Urine protein \< 1,000 mg by 24-hour urine collection (for patients with proteinuria ≥ 1+ by dipstick or urinalysis OR urine protein:creatinine ratio ≥ 1.0)
• No myocardial infarction within the past 6 months
• No unstable angina within the past 6 months
• No arterial thromboembolic events within the past 6 months, including any of the following:
• * Transient ischemic attack
• * Cerebrovascular accident
• * Clinically significant peripheral artery disease
• No unstable symptomatic arrhythmia requiring medication (e.g., chronic atrial arrhythmia \[i.e., atrial fibrillation or paroxysmal supraventricular tachycardia\])
• * Patients with an atrial arrhythmia are eligible provided the condition is well controlled on stable medication
• No New York Heart Association class II-IV congestive heart failure
• No history of arteriovenous malformation
• No history of aneurysm
• No uncontrolled hypertension (i.e., blood pressure \> 160/90 mm Hg with medication)
• No other clinically significant cardiac disease
• No AIDS
• No significant infection
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• Not pregnant
• No nursing during and for ≥ 3-4 months after completion of study treatment
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 3-4 months after completion of study treatment
• No history of gastrointestinal fistula or perforation
• No other malignancy within the past two years except nonmelanoma skin cancer or carcinoma in situ of the cervix, uterus, or bladder
• No significant traumatic injury within the past 4 weeks
• No serious nonhealing wound or ulcer
• No current healing fracture
• No known or suspected dihydropyrimidine dehydrogenase deficiency
• No other medical condition that would preclude study participation
• No concurrent interleukin-11
• No prior chemotherapy for pancreatic cancer
• More than 2 years since prior chemotherapy for another malignancy
• No prior radiotherapy to the planned irradiation field
• No concurrent intensity modulated radiotherapy
• No other concurrent radiotherapy
• See Disease Characteristics
• More than 4 weeks since prior major surgical procedure or open biopsy
• More than 1 week since prior fine needle aspiration or core biopsy
• No prior organ transplantation
• No concurrent major surgical procedure
• More than 30 days since prior and no concurrent cimetidine
• * Concurrent ranitidine or a drug from another anti-ulcer class allowed
• More than 4 weeks since prior and no concurrent sorivudine or brivudine
• No concurrent warfarin during chemoradiotherapy
• * Concurrent warfarin allowed beginning 2 weeks after completion of chemoradiotherapy
• * Concurrent low molecular weight heparin allowed (at any time during study participation)
• No other concurrent investigational agents
• No other concurrent cytotoxic agents